Patents by Inventor János Tibor Kodra

János Tibor Kodra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel glucagon antagonists
    Publication number: 20040152750
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 15, 2003
    Publication date: August 5, 2004
    Inventors: Janos Tibor Kodra, Carsten Behrens, Peter Madsen, Anker Steen Jorgensen, Inger Thoger Christensen
  • Glucagon antagonists
    Patent number: 6762318
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: July 13, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Aryl carbonyl derivatives as therapeutic agents
    Publication number: 20040122235
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: October 6, 2003
    Publication date: June 24, 2004
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Glucagon antagonists/inverse agonists
    Publication number: 20040024045
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Application
    Filed: February 24, 2003
    Publication date: February 5, 2004
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Novel glucagon antagonists/inverse agonists
    Publication number: 20040014789
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 22, 2004
    Inventors: Jesper Lau, Inge Thoger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Tibor Kodra, Poul Enrico Nielsen
  • Novel glucagon antagonists
    Publication number: 20030236292
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Glucagon antagonists/inverse agonists
    Publication number: 20030220350
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: August 30, 2002
    Publication date: November 27, 2003
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
  • Amide derivatives as therapeutic agents
    Publication number: 20030171411
    Abstract: This invention relates to compounds of the general formula 1
    Type: Application
    Filed: December 19, 2002
    Publication date: September 11, 2003
    Inventors: Janos Tibor Kodra, Jesper Lau, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti
  • Glucagon antagonists/inverse agonists
    Patent number: 6562807
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: May 13, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Glucagon antagonists/inverse agonists
    Publication number: 20020143186
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Application
    Filed: June 22, 2001
    Publication date: October 3, 2002
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau